Real-world use of quetiapine in early psychosis: An acute inpatient and community follow-up effectiveness study

Objective. To evaluate the use of quetiapine in first episode psychosis in adolescents and adults in a 26-week open-label trial. Methods. Consenting patients were recruited from consecutive acute psychiatric admissions. Quetiapine was increased stepwise to 750 mg. Baseline, 2, 4, 12, 16, 20 and 26 w...

Full description

Saved in:
Bibliographic Details
Published in:International journal of psychiatry in clinical practice 2008, Vol.12 (1), p.65-73
Main Authors: Victor Catts, Stanley, Desmond James Frost, Aaron, Gifford, Shaune, Scott, James
Format: Article
Language:English
Subjects:
acute care
Adolescence
Atypical antipsychotic
Clinical trials
consent
Drowsiness
Drug abuse
first episode psychosis
Hypotension
Posture
Psychosis
quetiapine
response prediction
substance abuse
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. To evaluate the use of quetiapine in first episode psychosis in adolescents and adults in a 26-week open-label trial. Methods. Consenting patients were recruited from consecutive acute psychiatric admissions. Quetiapine was increased stepwise to 750 mg. Baseline, 2, 4, 12, 16, 20 and 26 week measurement included: BPRS, PANSS, CGI, and indices of tolerability and safety. Change was assessed using repeated measures ANOVA. Results. Of 73 first admission patients with psychosis, 15 entered the study. Loss of otherwise eligible patients was mainly related to prospective consent, which appeared to cause selection bias. All 15 patients were retained for 4-week Intention-to-Treat Analysis; nine completed the 26-week protocol (Completers Analysis). Non-completers dropped out shortly after 4 weeks. In the ITT Analysis, there was significant improvement on BPRS Total (P
ISSN:1365-1501
1471-1788
1473-4885
DOI:10.1080/13651500701496733